Litcius/Paper detail

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Aditi R. Saxena, Donal Gorman, Ryan M. Esquejo, Arthur Bergman, Kristin Chidsey, Clare Buckeridge, David A. Griffith, Albert M. Kim

2021Nature Medicine143 citationsDOI

Topics & Concepts

MedicinePlaceboTolerabilityType 2 diabetesAdverse effectBlood pressureNauseaInternal medicinePharmacologyGlycemicDiabetes mellitusHeart rateMetforminEndocrinologyPathologyAlternative medicineDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial | Litcius